Skip to content

Proposed Tax Bill Would Cut Orphan Drug Tax Credit, Expand Medical Expense Support

Share this page

The House and Senate conferees have reached an agreement on the Tax Cuts and Jobs Act, and Congressional leaders are pushing hard to get the bill passed in both chambers this week. There is still a certain amount of political wrangling going on, but the key question now is not what the bill says so much as whether there are enough votes to pass it in both the Senate and the House. Of the provisions we have been watching closely, there was some good news and some bad news for the rare disease community.

The Medical Expense Deduction for individuals and families was slated for elimination in the House bill, but the Senate bill did not touch it. Current law allows families to take a deduction for medical expenses that amount to more than 10 percent of their income. The final tax reform bill would reduce that to 7.5 percent of family income, allowing more people to take advantage of the deduction and adding value to amount of the deduction.

It’s a different story for the Orphan Drug Tax Credit (ODTC), which currently allows companies to take a credit for 50 percent of their costs related to clinical trials for developing rare disease treatments. That credit was eliminated in the House bill, and reduced to 27.5 percent in the Senate bill. Currently, the final bill will reduce the credit to 25 percent. Although we are not pleased with a reduction to the value of the tax credit, it is a testament to the action undertaken by the rare disease community that the tax credit has not been eliminated altogether. Many of you made calls and sent emails, tweeted or posted your support for the ODTC on Facebook over the past several weeks. All of that work made a difference, and in the end, contributed to ensuring the ODTC was preserved in the final bill, even if it suffered a sizeable cut.

Related Articles